Securities code: Shanghai Haoyuan Chemexpress Co.Ltd(688131) securities abbreviation: Shanghai Haoyuan Chemexpress Co.Ltd(688131) Announcement No.: 2022033 Shanghai Haoyuan Chemexpress Co.Ltd(688131)
Special report on the deposit and use of raised funds in 2021
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear legal responsibility for the authenticity, accuracy and integrity of its contents according to law.
In accordance with the relevant provisions of the guidelines for the supervision of listed companies No. 2 – regulatory requirements for the management and use of raised funds by listed companies (revised in 2022) and the guidelines for the self discipline supervision of listed companies on the science and Innovation Board of Shanghai Stock Exchange No. 1 – standardized operation, the deposit and use of raised funds of the company in 2021 are reported as follows:
1、 Basic information of raised funds
(I) actual amount of raised funds and time of fund arrival
With the approval of the reply on Approving the registration of Shanghai Haoyuan Chemexpress Co.Ltd(688131) initial public offering (zjxk [2021] No. 1496) issued by China Securities Regulatory Commission on April 27, 2021, Shanghai Haoyuan Chemexpress Co.Ltd(688131) (hereinafter referred to as “the company” or ” Shanghai Haoyuan Chemexpress Co.Ltd(688131) “) publicly issued 18.6 million RMB common shares (A shares) to the public, with a par value of RMB 1 per share and an issue price of RMB 64.99 per share, The total amount of funds raised is 1208814 million yuan. After deducting the issuance expenses of 1006197 million yuan, the net amount of funds raised is 11081943 million yuan.
All the raised funds were in place on June 3, 2021. Rongcheng Certified Public Accountants (special general partnership) verified the availability of funds on June 3, 2021 and issued the capital verification report (Rongcheng Yan Zi [2021] No. 200z0026). The company carried out special account storage management for the above-mentioned raised funds in accordance with the regulations, and signed a supervision agreement on the storage of the special account of raised funds with the recommendation institution and the supervision Bank of the special account of raised funds.
(II) amount used in the current year and balance at the end of the year
As of December 31, 2021, the balance of the raised funds storage account is RMB 73969852387 (including the net amount of interest income deducted from the raised funds), and the use of the raised funds is as follows:
Unit: Yuan
Project amount
Net amount of raised funds 110819430986
Less: accumulated amount of raised funds invested (including amount invested in advance for replacement) 37883537091
Pay the corresponding VAT input tax 113910854 for the issuance expenses
Amount for cash management
Plus: net amount of interest income from raised funds and investment income from cash management deducting handling fees of 1131280478
The issuance fee that has not been replaced is 16588868
Outstanding issuance fees
As of December 31, 2021, the balance of raised funds was 73969852387
2、 Deposit and management of raised funds
(I) management system of raised funds
In order to standardize the management and use of raised funds and safeguard the legitimate rights and interests of all shareholders, The company has formulated and revised the measures for the administration of Shanghai Haoyuan Chemexpress Co.Ltd(688131) raised funds (hereinafter referred to as the “measures for the administration of raised funds”) in accordance with the requirements of the company law of the people’s Republic of China, the securities law of the people’s Republic of China, the guidelines for the supervision of listed companies No. 2 – regulatory requirements for the management and use of raised funds by listed companies (revised in 2022) and other relevant provisions, and implemented a special account storage system for the raised funds, Provisions are made on the storage and use of raised funds, project implementation management, change of investment projects and supervision of use.
(II) tripartite supervision agreement of raised funds
According to the requirements of Shanghai Stock Exchange and relevant regulations, the company, the sponsor Minsheng Securities Co., Ltd. (hereinafter referred to as “Minsheng securities”) and the bank where the special account for raising funds is located China Everbright Bank Company Limited Co.Ltd(601818) Shanghai pilot Free Trade Zone Branch, China Merchants Bank Co.Ltd(600036) Shanghai Shanghai Lujiazui Finance & Trade Zone Development Co.Ltd(600663) branch, China Citic Bank Corporation Limited(601998) Shanghai Nanfang Mall branch Bank Of China Limited(601988) Shanghai Fangdian road sub branch signed the tripartite supervision agreement on the storage of special account for raised funds (hereinafter referred to as the “tripartite supervision agreement”). There is no significant difference between the tripartite supervision agreement and the tripartite supervision agreement (model) on the storage of special account for raised funds of Shanghai Stock Exchange. There is no problem in the performance of the provisions of the agreement.
On July 12, 2021, the company held the 19th meeting of the second board of directors and the 9th meeting of the second board of supervisors, which respectively deliberated and approved the proposal on using the raised funds to increase capital to wholly-owned subsidiaries to implement raised investment projects and the proposal on wholly-owned subsidiaries opening special accounts for raised funds and signing quadripartite supervision agreements for the storage of raised funds, Among the projects raised and invested by the company, “Anhui Haoyuan biomedical R & D center construction project” and “Anhui Haoyuan pharmaceutical API and intermediate construction project with an annual output of 121095 tons (phase I)” are approved by the wholly-owned subsidiary of the company
Huihaoyuan Pharmaceutical Co., Ltd. (hereinafter referred to as “Anhui Haoyuan”). On July 19, 2021, the company, Anhui Haoyuan, Minsheng securities and China Construction Bank Corporation(601939) MAANSHAN branch signed the four party supervision agreement on the storage of special account for raised funds. The contents of the above four party supervision agreement are not significantly different from the three party supervision agreement (model) on the storage of special account for raised funds formulated by Shanghai Stock Exchange.
On October 25, 2021, the company held the 21st Meeting of the second board of directors and the 11th meeting of the second board of supervisors. On November 11, 2021, the company held the third extraordinary general meeting of shareholders in 2021 and deliberated and adopted the proposal on using part of the raised funds to invest in New projects, It is agreed that the company will use 306 million yuan to invest in the construction of “capital increase of Hefei ouchuang gene Biotechnology Co., Ltd. and the construction of pharmaceutical R & D and biological reagent R & D industrialization base project (phase I)”, “investment in Yantai Haoyuan Biomedical Technology Co., Ltd., a wholly-owned subsidiary, and provide loans to it with part of the over raised funds to build a new drug creation and R & D service base project (phase I)” “Invest in the construction of Shanghai Haoyuan Chemexpress Co.Ltd(688131) new drug creation service laboratory construction project (phase I)”, of which 289 million yuan of over raised funds is proposed to be used.
According to the above resolution, on November 12, 2021, the company signed the four party supervision agreement on the storage of the special account for raised funds with its subsidiary Hefei ouchuang gene Biotechnology Co., Ltd. (hereinafter referred to as “Hefei ouchuang”), the sponsor Minsheng securities and China Everbright Bank Company Limited Co.Ltd(601818) Hefei Branch, the bank where the special account for raised funds is located; On November 10, 2021, the company signed the four party supervision agreement on the deposit and storage of the special account for raised funds with its subsidiary Yantai Haoyuan Biomedical Technology Co., Ltd. (hereinafter referred to as “Yantai Haoyuan”), the sponsor Minsheng securities and Bank Of China Limited(601988) Yantai Development Zone sub branch where the special account for raised funds is located, There is no significant difference between the contents of the above four party supervision agreement and the tripartite supervision agreement (model) for the storage of raised funds formulated by Shanghai Stock Exchange.
(III) storage of raised funds in special account
As of December 31, 2021, the current deposit balance of the company’s special account for deposit of raised funds is as follows (unit: RMB):
Deposit balance of bank account number deposited by the account holder
mode
Haoyuanyi China Everbright Bank Company Limited Co.Ltd(601818) 76250188000136008 current 19950737322 pharmaceutical Shanghai pilot Free Trade Zone Branch
Haoyuanyi China Merchants Bank Co.Ltd(600036) Shanghai 121941334410402 current 29266393471 Medicine Shanghai Lujiazui Finance & Trade Zone Development Co.Ltd(600663) sub branch
Haoyuanyi China Citic Bank Corporation Limited(601998) Shanghai 8110201012801329910 current account-
Yaonanfang mall sub branch
Haoyuanyi Bank Of China Limited(601988) Shanghai 457281591887 current account-
Yaofangdian road sub branch
Anhui Hao China Construction Bank Corporation(601939) 34050165500809887666 current 13111619896 yuan MAANSHAN branch
Hefei Ou China Everbright Bank Company Limited Co.Ltd(601818) 548401805688000 current 7604360764 Chuang Hefei Branch
Yantai Hao Bank Of China Limited(601988) Yantai 223445272017 current 4036740934 Yuan Development Zone sub branch
Total – 73969852387
3、 Actual use of raised funds this year
(I) use of funds for investment projects with raised funds
For the comparison table of the actual use of the company’s raised funds in 2021, see the annex comparison table of the use of raised funds (Annex 1) to this report.
(II) cash management of idle raised funds
On July 12, 2021, the company held the 19th meeting of the second board of directors and the 9th meeting of the second board of supervisors respectively in order to improve the use efficiency of raised funds, make rational use of some temporarily idle raised funds, increase the company’s income and obtain more returns for the company and shareholders without affecting the construction and use of raised funds and the safety of raised funds, The proposal on using part of the temporarily idle raised funds for cash management was deliberated and passed, and it was agreed that the company would use the temporarily idle raised funds with an amount of no more than RMB 80 million (including this amount) for cash management under the premise of ensuring that the progress of the investment project of the raised funds, the normal production and operation of the company and the safety of funds The service life of financial products or deposit products with good liquidity and meeting the capital preservation requirements is 12 months after the deliberation and approval of the board of directors. Within the above limit and service life, the funds can be recycled and rolled. For details, see Shanghai Haoyuan Chemexpress Co.Ltd(688131) announcement on cash management with some temporarily idle raised funds (Announcement No.: 2021002).
In 2021, the company used a total of 1630 million yuan of raised funds for cash management, redeemed 1630 million yuan when due, and obtained a profit of 4.8076 million yuan. As of December 31, 2021, the balance of undue financial products or deposit products purchased with idle raised funds was RMB 10000. The unused raised funds will continue to be stored in a special account and used according to the planned investment progress.
(III) advance investment and replacement of investment projects with raised funds
According to the verification report on special instructions of Shanghai Haoyuan Chemexpress Co.Ltd(688131) using raised funds to replace the funds invested in the project with raised funds and pay the issuance expenses issued by Rongcheng Certified Public Accountants (special general partnership) (Rongcheng zhuanzi [2021] No. 200z0524), as of June 30, 2021, the actual investment amount of the company invested in the project invested with raised funds in advance with self raised funds was 10489628907 yuan; The company has used self raised funds to pay the issuance fee of 16588868 yuan (excluding value-added tax). The 19th meeting of the second board of directors and the 9th meeting of the second board of supervisors held on July 12, 2021 considered and approved the proposal on using raised funds to replace self raised funds invested in projects invested with raised funds in advance and paying issuance expenses in advance, and agreed that the company would use raised funds 10489628907 to replace self raised funds invested in projects invested with raised funds in advance, It is agreed that the company will use the raised funds to replace the self raised funds to pay the issuance fee of 16588868 yuan. For details, see Shanghai Haoyuan Chemexpress Co.Ltd(688131) the announcement on using the raised funds to replace the self raised funds invested in the raised investment projects and pay the issuance fee in advance (Announcement No.: 2021001).
(IV) temporary replenishment of working capital with idle raised funds
In 2021, there was no temporary replenishment of working capital with idle raised funds.
(V) permanent replenishment of working capital or repayment of bank loans with over raised funds
In combination with the company’s capital arrangement and business development plan in 2021, in order to meet the company’s working capital needs, improve the use efficiency of raised funds, reduce financial costs, further improve the company’s profitability and safeguard the interests of listed companies and shareholders, the company held the 19th meeting of the second board of directors and the 9th meeting of the second board of supervisors on July 12, 2021, The company held the second extraordinary general meeting of shareholders in 2021 and deliberated and adopted the
